Keyword: Charles River Laboratories
Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.
Melissa Pryce, senior supervisor, molecular biology, Charles River Laboratories
Gilead oncology EVP Riva joins Glenmark spinoff as CEO; Biocon's biosimilar plant dinged by FDA; Shionogi licenses Akili's digital therapeutics.
Charles River Laboratories has unloaded QS Pharma, a Philadelphia-area CDMO, months after picking it up as part of its $585 million buyout of WIL Research.